171 related articles for article (PubMed ID: 8993080)
1. Pharmacologic treatment of body dysmorphic disorder.
Phillips KA
Psychopharmacol Bull; 1996; 32(4):597-605. PubMed ID: 8993080
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
Phillips KA; Dwight MM; McElroy SL
J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
[TBL] [Abstract][Full Text] [Related]
3. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder.
Phillips KA
Psychopharmacol Bull; 1996; 32(1):175-80. PubMed ID: 8927669
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study.
Phillips KA; Albertini RS; Siniscalchi JM; Khan A; Robinson M
J Clin Psychiatry; 2001 Sep; 62(9):721-7. PubMed ID: 11681769
[TBL] [Abstract][Full Text] [Related]
5. Body dysmorphic disorder: diagnosis and treatment of imagined ugliness.
Phillips KA
J Clin Psychiatry; 1996; 57 Suppl 8():61-4; discussion 65. PubMed ID: 8698683
[TBL] [Abstract][Full Text] [Related]
6. An open-label study of citalopram in body dysmorphic disorder.
Phillips KA; Najjar F
J Clin Psychiatry; 2003 Jun; 64(6):715-20. PubMed ID: 12823088
[TBL] [Abstract][Full Text] [Related]
7. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness.
Hollander E; Allen A; Kwon J; Aronowitz B; Schmeidler J; Wong C; Simeon D
Arch Gen Psychiatry; 1999 Nov; 56(11):1033-9. PubMed ID: 10565503
[TBL] [Abstract][Full Text] [Related]
8. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach.
Phillips KA; Hollander E
Body Image; 2008 Mar; 5(1):13-27. PubMed ID: 18325859
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy of somatoform disorders.
Fallon BA
J Psychosom Res; 2004 Apr; 56(4):455-60. PubMed ID: 15094032
[TBL] [Abstract][Full Text] [Related]
10. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
Phillips KA; McElroy SL; Dwight MM; Eisen JL; Rasmussen SA
J Clin Psychiatry; 2001 Feb; 62(2):87-91. PubMed ID: 11247107
[TBL] [Abstract][Full Text] [Related]
11. An open-label study of escitalopram in body dysmorphic disorder.
Phillips KA
Int Clin Psychopharmacol; 2006 May; 21(3):177-9. PubMed ID: 16528140
[TBL] [Abstract][Full Text] [Related]
12. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.
Phillips KA
Am J Psychiatry; 2005 Feb; 162(2):377-9. PubMed ID: 15677604
[TBL] [Abstract][Full Text] [Related]
13. Body dysmorphic disorder and depression: theoretical considerations and treatment strategies.
Phillips KA
Psychiatr Q; 1999; 70(4):313-31. PubMed ID: 10587987
[TBL] [Abstract][Full Text] [Related]
14. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
Phillips KA; Albertini RS; Rasmussen SA
Arch Gen Psychiatry; 2002 Apr; 59(4):381-8. PubMed ID: 11926939
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy and psychotherapy for body dysmorphic disorder.
Ipser JC; Sander C; Stein DJ
Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD005332. PubMed ID: 19160252
[TBL] [Abstract][Full Text] [Related]
16. Body dysmorphic disorder--a fear of imagined ugliness.
Jefferys DE; Castle DJ
Aust Fam Physician; 2003 Sep; 32(9):722-5. PubMed ID: 14524210
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy for body dysmorphic disorder: treatment received and illness severity.
Phillips KA; Pagano ME; Menard W
Ann Clin Psychiatry; 2006; 18(4):251-7. PubMed ID: 17162625
[TBL] [Abstract][Full Text] [Related]
18. Recognizing and treating body dysmorphic disorder.
Grant JE; Phillips KA
Ann Clin Psychiatry; 2005; 17(4):205-10. PubMed ID: 16402752
[TBL] [Abstract][Full Text] [Related]
19. Body dysmorphic disorder: diagnostic controversies and treatment challenges.
Phillips KA
Bull Menninger Clin; 2000; 64(1):18-35. PubMed ID: 10695157
[TBL] [Abstract][Full Text] [Related]
20. Body Dysmorphic Disorder: Clinical Overview and Relationship to Obsessive-Compulsive Disorder.
Phillips KA; Kelly MM
Focus (Am Psychiatr Publ); 2021 Oct; 19(4):413-419. PubMed ID: 35747292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
